We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00602511
Recruitment Status : Completed
First Posted : January 28, 2008
Last Update Posted : February 9, 2011
Sponsor:
Information provided by:

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : September 2010
  Study Completion Date : December 2010